Cardio Diagnostics Holdings, Inc. CDIO
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2022 · data as of November 13, 2026
Cardio Diagnostics Holdings, Inc. (CDIO) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to September 30, 2026 it had revenue of $15185 and net income of -$6M, a net margin of -42721.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -92%.
About Cardio Diagnostics
Cardio Diagnostics is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2022. Revenue went from $901 in 2021 to $14825 in 2025, growth of about 101.4% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 1602% over three years (dilution for shareholders). It spends 4325% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $15185 | $14825 | $34890 | $17065 | $950 | $901 |
| Net income | -$6M | -$6M | -$8M | -$8M | -$5M | -$620448 |
| Free cash flow | -$6M | -$6M | -$5M | -$6M | — | — |
| EPS (diluted) | $-2.53 | $-3.71 | $-9.35 | $-19.80 | $-45.30 | $-15.90 |
| Net margin | -42721.9% | -43832.5% | -24028.2% | -49087.8% | -490600.0% | -68862.1% |
| ROIC | — | -69.2% | -66.2% | -158.9% | -105.7% | -58.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cardio Diagnostics pay a dividend?
Not currently.
Is Cardio Diagnostics a good stock to buy?
We do not give buy or sell advice. Cardio Diagnostics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.